Get the Stockscreener App
2.9754
1.20%
0.0354
After Hours:
2.98
0.0046
+0.15%
Lipocine Inc stock is traded at $2.9754, with a volume of 12,871.
It is up +1.20% in the last 24 hours and up +0.18% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.94
Open:
$2.96
24h Volume:
12,871
Relative Volume:
0.49
Market Cap:
$16.12M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-0.9755
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
+2.96%
1M Performance:
+0.18%
6M Performance:
-7.31%
1Y Performance:
-27.07%
1-Day Range:
$2.96
$3.01
1-Week Range:
$2.865
$3.02
52-Week Range:
$2.6838
$6.1683
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.9754 | 16.26M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Short interest data insights for Lipocine Inc.Product Launch & Safe Swing Trade Setup Alerts - Newser
Lipocine Inc. stock momentum explainedQuarterly Portfolio Summary & Low Drawdown Trading Strategies - Newser
Lipocine Inc. stock chart pattern explainedJuly 2025 Review & Entry Point Confirmation Signals - Newser
Can trapped investors hope for a rebound in Lipocine Inc.Market Growth Review & AI Driven Stock Reports - Newser
Forecasting Lipocine Inc. price range with options data2025 Dividend Review & Fast Gaining Stock Strategy Reports - Newser
Lipocine Inc. stock trendline breakdownWeekly Profit Report & Fast Gaining Stock Reports - Newser
Quantitative breakdown of Lipocine Inc. recent move2025 Price Targets & AI Enhanced Trading Signals - Newser
Sentiment analysis tools applied to Lipocine Inc.July 2025 Short Interest & AI Optimized Trade Strategies - Newser
Statistical indicators supporting Lipocine Inc.’s strength2025 Investor Takeaways & Verified Momentum Stock Alerts - Newser
Market reaction to Lipocine Inc.’s recent news2025 Trade Ideas & AI Powered Market Entry Strategies - Newser
Tick level data insight on Lipocine Inc. volatilityGold Moves & Safe Capital Allocation Plans - Newser
What indicators show strength in Lipocine Inc.Market Growth Report & Free Long-Term Investment Growth Plans - Newser
Published on: 2025-09-12 01:07:34 - Newser
Will Lipocine Inc. continue its uptrendProfit Target & Weekly Momentum Stock Picks - Newser
Has Lipocine Inc. formed a bullish divergenceMarket Performance Report & AI Powered Buy and Sell Recommendations - Newser
Sector ETF performance correlation with Lipocine Inc.July 2025 Weekly Recap & Fast Entry High Yield Stock Tips - Newser
Can Lipocine Inc. rally from current levels2025 Biggest Moves & Short-Term Trading Alerts - Newser
Does Lipocine Inc. qualify in momentum factor screening2025 Top Gainers & Free Weekly Watchlist of Top Performers - Newser
Analyzing net buyer seller activity in Lipocine Inc.2025 Historical Comparison & AI Based Buy and Sell Signals - Newser
Is now a turning point for Lipocine Inc.Weekly Profit Recap & Verified Technical Trade Signals - Newser
How to recover losses in Lipocine Inc. stockWeekly Profit Analysis & Reliable Volume Spike Alerts - Newser
Real time scanner hits for Lipocine Inc. explainedBull Run & Risk Controlled Stock Pick Alerts - Newser
Advanced analytics toolkit walkthrough for Lipocine Inc.Market Activity Report & Low Risk Entry Point Guides - Newser
Lipocine Inc. stock volume spike explainedMarket Sentiment Review & Entry Point Confirmation Signals - Newser
Relative strength of Lipocine Inc. in sector analysisWeekly Loss Report & High Conviction Trade Alerts - Newser
Strategies to average down on Lipocine Inc.Market Performance Recap & Verified Technical Trade Signals - Newser
Applying Elliott Wave Theory to Lipocine Inc.2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - Newser
Using Python tools to backtest Lipocine Inc. strategiesJuly 2025 EndofMonth & Daily Profit Focused Screening - Newser
Is Lipocine Inc. stock a smart retirement pickJuly 2025 WrapUp & Low Drawdown Trading Techniques - Lancaster City Council
What is Lipocine Inc. s revenue forecast2025 Retail Activity & Precise Swing Trade Alerts - Lancaster City Council
How to use Fibonacci retracement on Lipocine Inc.2025 Market Outlook & Free Risk Controlled Daily Trade Plans - Newser
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):